Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study

NCT07305428 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT07305428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07305428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Lead sponsor
The University of Hong Kong
Phase
Not applicable
Overall status
Recruiting
Start date
April 25, 2019
Completion date
December 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, unresectable hepatocellular carcinoma